Value Driver & Investor Multiple

Multiplying Your Invest:

Early STIMIT investors realized
a 3-fold multiple in <1 year.
New Investment Opportunity opening now.

STIMIT is at a tipping point and goes commercial with it’s medical device & unique business model in 2025.

2025

Sales Canada

2026

EU MDR

2027

USA FDA

Please contact info@stimit.com in case of investment interest

Problem:

During standard of care in critical care & ventilation, the diaphragm is lost by 50% in only 3 days¹, loss of breathing muscle and function is a key rootcause for prolonged ventilation².

cost of prolonged ventilation in USA alone: >16 billion³ $
Representing 300.000 patients on prolonged ventilation (USA only) out of 20 million ventilated patients worldwide.

[1] Levine et al. 2008

[2] Goligher et al. 2021

[3] Zilberberg et al. 2012

Solution:

The diaphragm stimulation market is emerging, with 5 pioneers, of which STIMIT is the first non-invasive solution.
This emerging market represents a 2 billion revenue opportunity in USA alone.

STIMIT IS ADRESSING 3 MEGA TRENDS IN RESPIRATORY & CRITICAL CARE:
- NEUROSTIMULATION
- EMPOWER PATIENTS TO BREATHE
- EARLY INTERVENTION

“STIMIT holds immense potential to revolutionize the landscape of intensive care units and ventilation in all its dimensions in the future.”
Consensus of world leading respiratory care physicians (reference letters on file)

STIMIT AG

Aarbergstrasse 46
CH-2503 Biel/Bienne
Switzerland

Contact

Email: info@stimit.com
Tel: +41 32 513 93 00